Please use this identifier to cite or link to this item:
Title: Lower Locus Coeruleus MRI intensity in patients with late-life major depression
Author: Guinea Izquierdo, Andrés
Giménez, Mònica
Martínez Zalacaín, Ignacio
Cerro San Ildefonso, Inés del
Canal Noguer, Pol
Blasco, Gerard
Gascón-Bayarri, Jordi
Reñé Ramírez, Ramon
Rico, Inmaculada
Camins, Àngels
Aguilera, Carles
Urretavizcaya Sarachaga, Mikel
Ferrer, Isidro (Ferrer Abizanda)
Menchón Magriñá, José Manuel
Soria, Virginia
Soriano Mas, Carles
Keywords: Neurociència cognitiva
Malalties del sistema nerviós central
Cognitive neuroscience
Central nervous system diseases
Issue Date: 16-Feb-2021
Publisher: PeerJ
Abstract: Background: The locus coeruleus (LC) is the major noradrenergic source in the central nervous system. Structural alterations in the LC contribute to the pathophysiology of different neuropsychiatric disorders, which may increase to a variable extent the likelihood of developing neurodegenerative conditions. The characterization of such alterations may therefore help to predict progression to neurodegenerative disorders. Despite the LC cannot be visualized with conventional magnetic resonance imaging (MRI), specific MRI sequences have been developed to infer its structural integrity. Methods: We quantified LC signal Contrast Ratios (LCCRs) in late-life major depressive disorder (MDD) (n = 37, 9 with comorbid aMCI), amnestic Mild Cognitive Impairment (aMCI) (n = 21, without comorbid MDD), and healthy controls (HCs) (n = 31), and also assessed the putative modulatory effects of comorbidities and other clinical variables. Results: LCCRs were lower in MDD compared to aMCI and HCs. While no effects of aMCI comorbidity were observed, lower LCCRs were specifically observed in patients taking serotonin/norepinephrine reuptake inhibitors (SNRIs). Conclusion: Our results do not support the hypothesis that lower LCCRs characterize the different clinical groups that may eventually develop a neurodegenerative disorder. Conversely, our results were specifically observed in patients with late-life MDD taking SNRIs. Further research with larger samples is warranted to ascertain whether medication or particular clinical features of patients taking SNRIs are associated with changes in LC neurons.
Note: Reproducció del document publicat a:
It is part of: PeerJ, 2021, vol. 9
Related resource:
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
peerj-10828.pdf2.26 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons